Chromatographic analysis of triple cough therapy; bromhexine, guaiafenesin and salbutamol and pharmaceutical impurity: in-silico toxicity profile of drug impurity

Table 4 Findings of the developed methods for the analysis of laboratory prepared mixtures, the two pharmaceutical dosage forms and the application of standard addition technique

	TLC	HPLC
Laboratory prepared mixtures^a (Mean ± %RSD)
GUF BR SAL GUL	99.64 ± 1.27 99.51 ± 1.11 100.20 ± 1.06 99.90 ± 0.89	99.17 ± 2.31 98.16 ± 1.23 98.29 ± 1.59 100.3876 ± 1.34
Pharmaceutical formulation^b (With sugar) (Mean ± %RSD)
GUF BR SAL	99.61 ± 1.61 94.16 ± 2.19 99.89 ± 1.52	101.44 ± 2.29 94.59 ± 2.46 99.34 ± 1.96
Pharmaceutical formulation^b (Without sugar) (Mean ± %RSD)
GUF BR SAL	96.20 ± 2.00 97.52 ± 2.83 95.89 ± 1.63	96.72 ± 1.84 98.56 ± 2.16 96.95 ± 1.67
Standard addition^c (with sugar) (Mean ± STD)
GUF BR SAL	99.21 ± 1.46 99.05 ± 1.13 99.04 ± 1.33	99.47 ± 1.19 99.28 ± 1.76 100.37 ± 1.37
Standard addition^c (without sugar) (Mean ± %RSD)
GUF BR SAL	99.28 ± 1.38 98.69 ± 1.36 99.58 ± 1.49	99.29 ± 1.98 98.73 ± 1.57 97.61 ± 1.04

^aAverage of determinations of six laboratory prepared mixtures each was analyzed in triplicates
^bAverage of 6 determinations (For TLC-densitometeric method, the measured concentrations were 1.00, 0.80 and 0.40 for GUF, BR, and SAL, respectively. While for HPLC, Concentrations were 25, 20, 10 for GUF, BR and SAL, respectively)
^cAverage of 3 determinations of standard addition samples
For TLC, the added concentrations to the prepared dosage forms were: For GUF: 1.00, 2.00 and 3.00 µg /band, For each of BR or SAL: 0.2, 0.50 and 1.00 µg /band
For HPLC, the added concentrations were: For GUF:15, 20, and 25 µg /mL, For each of BR or SAL: 10, 15, and 20 for BR and SAL, in order)

ISSN: 2661-801X